Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Company Snapshot
All eyes on Gilead as hep C market opens up
With a strong pipeline and recent listings and approvals in Hep C and HIV, Gilead certainly has a lot going on.
Pipeline Monitor
New month brings pipeline flood
The 2016 year is well and truly underway with a sudden rush of new overseas approvals, including MSD's new hep C treatment and an additional indication for Eisai's Halaven.
Working Life
A day in the life: medical information associate
In the first of a new series, we talk to Kelly Sun, medical information associate at Mundipharma about her job and a typical working day.
Approvals Action
Thyroid cancer blockbuster given go ahead
Japan's Eisai has won Australian registration for Lenvima, the company's anticipated blockbuster to treat thyroid cancer.
Special Report
Biosimilars: what does 2016 hold?
Rapid uptake of biosimilars is being promoted by the GBMA as the path to future PBS savings but their immediate prospects remain clouded by regulatory and reimbursement issues.